Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Expression of microRNA-379 reduces metastatic spread of prostate cancer

Cassidy, James R. LU ; Voss, Gjendine LU ; Underbjerg, Kira Rosenkilde LU ; Persson, Margareta LU and Ceder, Yvonne LU orcid (2023) In Frontiers in Oncology 13.
Abstract

Introduction: Prostate cancer (PCa) is the most common type of cancer in males, and the metastatic form is a leading cause of death worldwide. There are currently no curative treatments for this subset of patients. To decrease the mortality of this disease, greater focus must be placed on developing therapeutics to reduce metastatic spread. We focus on dissemination to the bone since this is both the most common site of metastatic spread and associated with extreme pain and discomfort for patients. Our strategy is to exploit microRNAs (miRNAs) to disrupt the spread of primary PCa to the bone. Methods: PCa cell lines were transduced to overexpress microRNA-379 (miR-379). These transduced PCa cells were assessed using cell growth,... (More)

Introduction: Prostate cancer (PCa) is the most common type of cancer in males, and the metastatic form is a leading cause of death worldwide. There are currently no curative treatments for this subset of patients. To decrease the mortality of this disease, greater focus must be placed on developing therapeutics to reduce metastatic spread. We focus on dissemination to the bone since this is both the most common site of metastatic spread and associated with extreme pain and discomfort for patients. Our strategy is to exploit microRNAs (miRNAs) to disrupt the spread of primary PCa to the bone. Methods: PCa cell lines were transduced to overexpress microRNA-379 (miR-379). These transduced PCa cells were assessed using cell growth, migration, colony formation and adhesion assays. We also performed in vivo intracardiac injections to look at metastatic spread in NSG mice. A cytokine array was also performed to identify targets of miR-379 that may drive metastatic spread. Results: PCa cells with increased levels of miR-379 showed a significant decrease in proliferation, migration, colony formation, and adhesion to bone cells in vitro. In vivo miR-379 overexpression in PC3 cells significantly decreased metastatic spread to bone and reduced levels of miR-379 were seen in patients with metastases. We identified GDF-15 to be secreted from osteoblasts when grown in conditioned media from PCa cells with reduced miR-379 levels. Discussion: Taken together, our in vitro and in vivo functional assays support a role for miR-379 as a tumour suppressor. A potential mechanism is unravelled whereby miR-379 deregulation in PCa cells affects the secretion of GDF-15 from osteoblasts which in turn facilitates the metastatic establishment in bone. Our findings support the potential role of miR-379 as a therapeutic solution for prostate cancer.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
disease management, microRNAs, MIRN379, neoplasm metastasis, prostatic cancer, tumour microenvironment
in
Frontiers in Oncology
volume
13
article number
1252915
publisher
Frontiers Media S. A.
external identifiers
  • scopus:85172289664
  • pmid:37781173
ISSN
2234-943X
DOI
10.3389/fonc.2023.1252915
language
English
LU publication?
yes
additional info
Publisher Copyright: Copyright © 2023 Cassidy, Voss, Underbjerg, Persson and Ceder.
id
48351fdb-2b13-4a5b-b9a1-1d2518dcfed3
date added to LUP
2024-07-02 09:39:51
date last changed
2024-07-16 12:51:38
@article{48351fdb-2b13-4a5b-b9a1-1d2518dcfed3,
  abstract     = {{<p>Introduction: Prostate cancer (PCa) is the most common type of cancer in males, and the metastatic form is a leading cause of death worldwide. There are currently no curative treatments for this subset of patients. To decrease the mortality of this disease, greater focus must be placed on developing therapeutics to reduce metastatic spread. We focus on dissemination to the bone since this is both the most common site of metastatic spread and associated with extreme pain and discomfort for patients. Our strategy is to exploit microRNAs (miRNAs) to disrupt the spread of primary PCa to the bone. Methods: PCa cell lines were transduced to overexpress microRNA-379 (miR-379). These transduced PCa cells were assessed using cell growth, migration, colony formation and adhesion assays. We also performed in vivo intracardiac injections to look at metastatic spread in NSG mice. A cytokine array was also performed to identify targets of miR-379 that may drive metastatic spread. Results: PCa cells with increased levels of miR-379 showed a significant decrease in proliferation, migration, colony formation, and adhesion to bone cells in vitro. In vivo miR-379 overexpression in PC3 cells significantly decreased metastatic spread to bone and reduced levels of miR-379 were seen in patients with metastases. We identified GDF-15 to be secreted from osteoblasts when grown in conditioned media from PCa cells with reduced miR-379 levels. Discussion: Taken together, our in vitro and in vivo functional assays support a role for miR-379 as a tumour suppressor. A potential mechanism is unravelled whereby miR-379 deregulation in PCa cells affects the secretion of GDF-15 from osteoblasts which in turn facilitates the metastatic establishment in bone. Our findings support the potential role of miR-379 as a therapeutic solution for prostate cancer.</p>}},
  author       = {{Cassidy, James R. and Voss, Gjendine and Underbjerg, Kira Rosenkilde and Persson, Margareta and Ceder, Yvonne}},
  issn         = {{2234-943X}},
  keywords     = {{disease management; microRNAs; MIRN379; neoplasm metastasis; prostatic cancer; tumour microenvironment}},
  language     = {{eng}},
  publisher    = {{Frontiers Media S. A.}},
  series       = {{Frontiers in Oncology}},
  title        = {{Expression of microRNA-379 reduces metastatic spread of prostate cancer}},
  url          = {{http://dx.doi.org/10.3389/fonc.2023.1252915}},
  doi          = {{10.3389/fonc.2023.1252915}},
  volume       = {{13}},
  year         = {{2023}},
}